Symbol="OCUL"
AssetType="Common Stock"
Name="Ocular Therapeutix Inc"
Description="Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts."
CIK="1393434"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="24 CROSBY DRIVE, BEDFORD, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="350412000"
EBITDA="-81890000"
PERatio="None"
PEGRatio="0"
BookValue="0.039"
DividendPerShare="0"
DividendYield="0"
EPS="-1.16"
RevenuePerShareTTM="0.706"
ProfitMargin="-1.662"
OperatingMarginTTM="-1.539"
ReturnOnAssetsTTM="-0.355"
ReturnOnEquityTTM="-2.634"
RevenueTTM="54602000"
GrossProfitTTM="-6508000"
DilutedEPSTTM="-1.16"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.238"
AnalystTargetPrice="13.13"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.174"
PriceToBookRatio="4.898"
EVToRevenue="3.321"
EVToEBITDA="-3.283"
Beta="1.221"
num_52WeekHigh="7.96"
num_52WeekLow="2.57"
num_50DayMovingAverage="4.992"
num_200DayMovingAverage="4.697"
SharesOutstanding="77525000"
DividendDate="None"
ExDividendDate="None"
symbol="OCUL"
open="4.41"
high="4.44"
low="4.30"
price="4.31"
volume="907323.00"
latest_trading_day="2023-08-17"
previous_close="4.40"
change="-0.09"
change_percent="-2.0455%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="43"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="57"
Volume_recent_avg="1112657"
Change_recent_avg="-0.02"
Delta_recent_avg="0.33"
Variance_recent_avg="0.16"
Change_ratio_recent_avg="-0.36"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="57"
Aroon_momentum_negative="43"
image_negative_thumbnail_id_1="494"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0111.jpeg"
image_negative_thumbnail_id_2="504"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0101.jpeg"
image_neutral_thumbnail_id_1="577"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0022.jpeg"
image_neutral_thumbnail_id_2="592"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0007.jpeg"
image_positive_thumbnail_id_1="1011"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0173.jpeg"
image_positive_thumbnail_id_2="673"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0035.jpeg"
image_professor_thumbnail_id_1="1186"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0020.jpeg"
image_professor_thumbnail_id_2="1169"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
